Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Gunst JD. et al, (2025), Nature Communications, 16
MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.
Dolton G. et al, (2025), The Journal of clinical investigation, 135
Learning patterns of HIV-1 resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning
Igiraneza AB. et al, (2024), PLOS Computational Biology, 20, e1012618 - e1012618
Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection
Sun W. et al, (2024), Journal of Experimental Medicine, 221
Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption
Tipoe T. et al, (2024), European Journal of Immunology
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Ali M. et al, (2024), Clinical and Experimental Immunology
Prevalence of resistance-associated viral variants to the HIV-specific broadly neutralising antibody 10-1074 in a UK bNAb-naïve population
Zacharopoulou P. et al, (2024), Frontiers in Immunology, 15
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Nel C. and Frater J., (2024), Frontiers in immunology, 15
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
Thornhill JP. et al, (2023), AIDS (London, England)
Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.
Kopycinski J. et al, (2023), Sci Rep, 13
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Barnes E. et al, (2023), Nature Medicine, 29, 1760 - 1774
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Murray SM. et al, (2023), Nature Reviews Immunology, 23, 304 - 316
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
Paediatric HIV slow-progression is associated with early CD8+ T-cell PD-1 expression and a stem-like phenotype.
Adriano Vieira V. et al, (2023), JCI insight
A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117
Zacharopoulou P. et al, (2022), Current Opinion in HIV and AIDS, 17, 352 - 358
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells
Sampson O. et al, (2022), Journal of Immunological Methods, 504, 113263 - 113263